Findings

What do systematic reviews say?

10 questions · 10 findings · 2 reviews · Breast Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 4 · 40%Low 4 · 40%Moderate 2 · 20%High 0 · 0%

Tamoxifen vs placebo

Overall breast cancer incidence · women with above‐average risk of developing breast cancer

Tamoxifen probably leads to lower overall breast cancer incidence compared with placebo (moderate certainty).

1 finding from 1 review

Risk‐reducing medications for primary breast cancer: a network meta‐analysis 2019 · Cochrane Headline outcomes only
RR 0.68 [0.62, 0.76]
3 studies · 22832 participants
Moderate

Tamoxifen vs placebo

Severe toxicity · women with above‐average risk of developing breast cancer

Tamoxifen probably leads to higher severe toxicity compared with placebo (moderate certainty).

1 finding from 1 review

Risk‐reducing medications for primary breast cancer: a network meta‐analysis 2019 · Cochrane Headline outcomes only
RR 1.28 [1.12, 1.47]
2 studies · 20361 participants
Moderate

Intervention not reported

Breast cancer mortality ‐ tamoxifen · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)

1 finding from 1 review

Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 97 participants
Low

Intervention not reported

Recurrence ‐ tamoxifen · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)

1 finding from 1 review

Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1956 participants
Very low

Intervention not reported

Recurrence (loco‐regional) ‐ endocrine therapies not separated (exemestane (AI)/tamoxifen (SERM)) · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)

1 finding from 1 review

Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 284 participants
Very low

Intervention not reported

Recurrence (distance) ‐ endocrine therapies not separated (exemestane (AI)/tamoxifen (SERM)) · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)

1 finding from 1 review

Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 284 participants
Very low

Intervention not reported

Incidence of a secondary primary breast cancer (e.g. in the contralateral breast) ‐ endocrine therapies not separated (exemestane (AI)/tamoxifen (SERM)/unknown) · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)

1 finding from 1 review

Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 87 participants
Very low

Intervention not reported

Incidence of invasive breast cancer and DCIS ‐ tamoxifen · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)

1 finding from 1 review

Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 51 participants
Low

Intervention not reported

Prevention: incidence of invasive breast cancer and DCIS ‐ tamoxifen · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor) or not receiving endocrine therapy…

1 finding from 1 review

Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 123 participants
Low

Aromatase inhibitors vs tamoxifen (indirect comparison)a

Overall breast cancer incidence · women with above‐average risk of developing breast cancer

Aromatase inhibitors may leads to lower overall breast cancer incidence compared with tamoxifen (indirect comparison)a (low certainty).

1 finding from 1 review

Risk‐reducing medications for primary breast cancer: a network meta‐analysis 2019 · Cochrane Headline outcomes only
RR 0.67 [0.46, 0.98]
5 studies · 31256 participants
Low